Fig. 4

Characterization of immune signatures in public population. a) Distribution of PD-L1 expression in TCGA LUAD patients. The dashed lines denote 1st quantile, median and 3rd quantile. b) The percentages of immune subtypes in PD-L1 high and negative expression subgroups. The normalized ssGSEA scores of c) IFN-gamma, d) CD8+ T cells, e) NK cells and f) Th cells in PD-L1 high and negative expression subgroups. Kaplan–Meier estimates of g) progression-free survival (Rizvi cohort) and h) overall survival (MSKCC cohort) in the groups with or without SETD2 mutations. The normalized ssGSEA scores of i) IFN-gamma and j) CD8+ T cells in the groups with or without SETD2 mutations. LUAD, lung adenocarcinoma; IFN, interferon;NK cells, natural killer cells; Th cells, T helper cells; PFS, progression-free survival; OS, overall survival. ‘ns’, not significant. *P < 0.05, **P < 0.01, ****P < 0.0001